EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC-ND 4.0

Efficacy of Low‐Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12‐Month Randomised, Double‐Blind, Placebo‐Controlled Single‐Centre Clinical Trial ( INNOVA Study)

Carla Rodríguez-Freire iD, Jaime Navarrete iD, Antoni Rozadilla-Sacanell iD, Juan P Sanabria-Mazo iD, Beatriz Del Pino-Gaya, Xavier Borràs iD, Albert Feliu-Soler iD, Juan V Luciano iD

European Journal of Pain · 2026

DOI: 10.1002/ejp.70321 ↗

At a glance

Randomisierte kontrollierte Studie in European Journal of Pain, 2026. Written by Carla Rodríguez-Freire and 7 co-authors. Institution: Teaching, Research & Innovation Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain. Major MEDLINE topics: Fibromyalgia, Naltrexone, Narcotic Antagonists. Cited 2 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Low‐dose naltrexone (LDN) has been used off‐label for fibromyalgia syndrome (FMS) for over a decade, supported by small crossover trials. The INNOVA study evaluated the safety and efficacy of LDN 4.5 mg versus placebo on pain intensity over 12 months in women with FMS.

Methods

In total, 98 women with FMS were randomised to LDN 4.5 mg/day ( n = 48) or placebo ( n = 50). The primary outcome was change in pain intensity (NRS 0–10) from baseline to 3 months in the intention‐to‐treat population. Secondary outcomes included functional impairment (FIQR), anxiety‐depressive symptoms (DASS‐21), cognitive impairment (MISCI), disability (WHODAS 2.0), pathological worry (GAD‐7) and impression of change (PGIC/PSIC), assessed at baseline and at 3, 6 and 12 months. Perceived treatment allocation and safety were also assessed.

Results

At 3 months, mean change in pain intensity was −0.33 points with LDN and −0.64 with placebo, with an adjusted between‐group difference of 0.49 ( p = 0.236, d = 0.19). Secondary outcomes showed minor and inconsistent changes, with low and similar responder rates ( p = 0.219–0.954). Exploratory analyses suggested some improvement among participants who believed they had received LDN, although effects were inconsistent. Adverse events, predominantly mild and transient, were reported by 33 (68.8%) participants in LDN and 36 (72%) in placebo, and no treatment‐related serious events occurred.

Conclusions

LDN was well tolerated but did not demonstrate a clinically meaningful benefit over placebo for pain‐related outcomes, underscoring the need for more effective pharmacological treatments. Significance Statement This RCT provides the first long‐term evidence on the efficacy and safety of LDN in FMS. LDN (4.5 mg), administered as an add‐on treatment, has a favourable safety profile, but the findings indicate that it does not produce clinically meaningful improvements in FMS symptoms compared to placebo at short‐ or long‐term follow‐up. These findings contribute to the growing body of evidence questioning its clinical utility.

Subjects

MeSH terms (MEDLINE)

FibromyalgiaNaltrexoneNarcotic AntagonistsHumansFemaleDouble-Blind MethodMiddle AgedTreatment OutcomeAdultPain Measurement

Author keywords

chronic painfibromyalgia syndromelow‐dose naltrexonerandomised controlled trial

Substances

NaltrexoneNarcotic Antagonists

Authors and institutions

  • Teaching, Research & Innovation Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain.
  • Centre for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Department of Rheumatology, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain.
  • Unit for the Study and Treatment of Pain-ALGOS, Department of Psychology, Research Center for Behavior Assessment (CRAMC), Universitat Rovira i Virgili, Tarragona, Spain.
  • Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, Spain.
  • Department of Pharmacy, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain.

ORCID profiles: Carla Rodríguez-Freire, Jaime Navarrete, Antoni Rozadilla-Sacanell, Juan P Sanabria-Mazo, Xavier Borràs, Albert Feliu-Soler, Juan V Luciano

Cite

APA

Rodríguez-Freire, C., Navarrete, J., Rozadilla-Sacanell, A., Sanabria-Mazo, J. P., Del Pino-Gaya, B., Borràs, X., Feliu-Soler, A., & Luciano, J. V. (2026). Efficacy of Low‐Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12‐Month Randomised, Double‐Blind, Placebo‐Controlled Single‐Centre Clinical Trial ( INNOVA Study). European Journal of Pain. https://doi.org/10.1002/ejp.70321

Vancouver

Rodríguez-Freire C, Navarrete J, Rozadilla-Sacanell A, Sanabria-Mazo JP, Del Pino-Gaya B, Borràs X, et al. Efficacy of Low‐Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12‐Month Randomised, Double‐Blind, Placebo‐Controlled Single‐Centre Clinical Trial ( INNOVA Study). European Journal of Pain. 2026. doi:10.1002/ejp.70321

BibTeX
@article{RodrguezFreire2026,
  author = {Rodríguez-Freire, Carla and Navarrete, Jaime and Rozadilla-Sacanell, Antoni and Sanabria-Mazo, Juan P and Del Pino-Gaya, Beatriz and Borràs, Xavier and Feliu-Soler, Albert and Luciano, Juan V},
  title = {Efficacy of Low‐Dose Naltrexone in Women With Fibromyalgia Syndrome: A 12‐Month Randomised, Double‐Blind, Placebo‐Controlled Single‐Centre Clinical Trial ( INNOVA Study)},
  journal = {European Journal of Pain},
  year = {2026},
  doi = {10.1002/ejp.70321}
}
Start for free →